$1.1 Million EBITDA, Electrotherapy TENS Device Company in Texas

Company Overview

American HealthCare Capital and Allied Healthcare Advisors are pleased to exclusively introduce a well-established medical device company specializing in non-invasive electro-therapy solutions designed to alleviate pain and improve patient outcomes. The company has built a strong reputation over more than two decades by providing high-quality Transcutaneous Electrical Nerve Stimulation (TENS) devices and related therapeutic products to healthcare providers and their patients.

Core Competencies

• Strong physician and therapist referral network driving consistent revenue

• Robust compliance program

• Customized, easy-to-use electro-therapy devices that support at-home patient care

• Decades of industry experience with a loyal customer base

• Scalable business model with recurring revenue streams

Differentiators

• High revenue growth of 84% CAGR over 3 years

• Strong Adjusted EBITDA Margins of 38% and Gross Profit Margin of 77%

• Patient growth rates of 87% CAGR from 218 to 1,443 over 3 years

• Robust compliance program

• Physician and Therapist-driven referrals, ensuring strong medical credibility and patient retention

Product and Payer Mix

The Company’s product mix is 90% Electrodes, 5% TENS Devices, and 5% Braces. The Company’s payer mix consists of 100% Commercial Insurance.

Staff Overview

The Company’s team is expected to remain in place under new ownership, including 8 employees and 7 independent contractors.

Financial Overview

The Company’s revenue has increased significantly from 2022 to 2025 at a compounded annual growth rate (CAGR) of 84% while achieving a 34% adjusted EBITDA margin. The Company expects to continue its double-digit growth rates from a strong first quarter of new patients in 2026.  Total 2026 revenues are forecasted to grow to $2.9 million and $1.1 million in Adjusted EBITDA (38%).

2023 Patients: 693 | Revenue: $944,614 | Adjusted EBITDA: -$112,633 | Margin: -12%
2024 Patients: 985 | Revenue: $1,404,785 | Adjusted EBITDA: $242,121 | Margin: 17%
2025 Patients: 1,443 | Revenue: $2,490,726 | Adjusted EBITDA: $850,028 | Margin: 34%
2026 Forecast Patients: 1,700 | Revenue: $2,900,000 | Adjusted EBITDA: $1,100,000 | Margin: 38%

Asking Price

The asking price is $9 Million plus an earn-out going forward. The Seller will consider a majority sale and rollover of equity while remaining involved post-close. This does not include cash, receivables, or working capital.